GALENA BIOPHARMA
Galena Biopharma, Inc. (Galena) is a biotechnology company focused on discovering, developing and commercializing therapies addressing unmet medical needs using targeted biotherapeutics. The Company is pursuing the development of cancer therapeutics using peptide-based immunotherapy products, including its main product candidate, NeuVaxTM (E75), for the treatment of breast cancer and other tumors. NeuVax is a peptide-based immunotherapy intended to reduce the recurrence of breast cancer in low-to-intermediate HER2-positive breast cancer patients not eligible for trastuzumab (Herceptin; Genentech/Roche). In January 2014, Galena Biopharma Inc acquired Mills Pharmaceuticals, which has the worldwide rights to GALE-401 (Anagrelide CR), a patented, controlled release formulation of anagrelide.
GALENA BIOPHARMA
Industry:
Biotechnology Health Diagnostics Medical
Founded:
2003-01-01
Address:
Portland, Oregon, United States
Country:
United States
Website Url:
http://www.galenabiopharma.com
Total Employee:
51+
Status:
Active
Contact:
+118558554253
Email Addresses:
[email protected]
Total Funding:
33.1 M USD
Technology used in webpage:
Google Analytics Apache Google Analytics Classic Unified Layer CentOS Apache 2.2 BlueHost
Similar Organizations
Advanced Cell Diagnostics
Advanced Cell Diagnostics is a molecular pathology company developing cell- and tissue-based diagnostic tests for personalized medicine.
Scholar Rock
Scholar Rock is a biopharmaceutical company that develops and discovers new medicines and treatments for the serious diseases.
Current Employees Featured
Founder
Stock Details
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2017-08-14 | SELLAS Life Sciences | SELLAS Life Sciences acquired by Galena Biopharma | N/A |
Official Site Inspections
http://www.galenabiopharma.com
- Host name: 172.67.170.148
- IP address: 172.67.170.148
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
